中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 5
May  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(5): 1178-1183

Advances in the application of nonselective β-receptor blockers in treatment of liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2023.05.028
  • a.

    Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, China

  • b.

    Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu 610041, China

Research funding:

International Cooperation Project of Sichuan Provincial Science and Technology Department (2021YFH0099)

More Information
  • Corresponding author: WANG Xiaoze, wang_xiaoze@wchscu.cn (ORCID: 0000-0002-7169-9467)
  • Received Date: 2022-11-04
  • Accepted Date: 2022-12-05
  • Published Date: 2023-05-20
    Abstract
  • Nonselective β-receptor blockers (NSBBs) are first-line drugs for the prevention and treatment of complications in cirrhotic patients with portal hypertension and are widely used in the primary and secondary prevention of esophagogastric variceal bleeding. In recent years, studies have shown that in patients with clinically significant portal hypertension (CSPH), NSBBs can used to prevent liver decompensation events besides variceal bleeding, such as ascites and hepatic encephalopathy. However, in patients without CSPH, current research evidence does not support the use of NSBBs. Although reliable data currently support the use of NSBBs in end-stage liver cirrhosis, there are still drug safety issues in patients with refractory ascites and spontaneous bacterial peritonitis, and further studies are needed to explore the dose and timing of administration. This article reviews the clinical research advances in the use of NSBBs (especially carvedilol) in patients with liver cirrhosis and summarizes the therapeutic window used reasonably in the whole-course management of liver cirrhosis, so as to provide a basis for clinical decision-making.

     

    • FullText(HTML)
  • loading
    • References(41)
  • [1]
    GRACIA-SANCHO J, MARRONE G, FERNÁNDEZ-IGLESIAS A. Hepatic microcirculation and mechanisms of portal hypertension[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(4): 221-234. DOI: 10.1038/s41575-018-0097-3.
    [2]
    LEBREC D, NOUEL O, CORBIC M, et al. Propranolol-a medical treatment for portal hypertension?[J]. Lancet, 1980, 2(8187): 180-182. DOI: 10.1016/s0140-6736(80)90063-x.
    [3]
    D'AMICO G, GARCIA-PAGAN JC, LUCA A, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review[J]. Gastroenterology, 2006, 131(5): 1611-1624. DOI: 10.1053/j.gastro.2006.09.013.
    [4]
    GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906.
    [5]
    de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
    [6]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Endoscopy, Chinese Medical Association. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002.
    [7]
    SINAGRA E, PERRICONE G, D'AMICO M, et al. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis[J]. Aliment Pharmacol Ther, 2014, 39(6): 557-568. DOI: 10.1111/apt.12634.
    [8]
    de FRANCHIS R, Baveno Ⅵ Faculty. Expanding consensus in portal hypertension: Report of the Baveno Ⅵ Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
    [9]
    GLUUD LL, KRAG A. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults[J]. Cochrane Database Syst Rev, 2012, 8(8): CD004544. DOI: 10.1002/14651858.CD004544.pub2.
    [10]
    ROCCARINA D, BEST LM, FREEMAN SC, et al. Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis[J]. Cochrane Database Syst Rev, 2021, 4(4): CD013121. DOI: 10.1002/14651858.CD013121.pub2.
    [11]
    SHARMA M, SINGH S, DESAI V, et al. Comparison of therapies for primary prevention of esophageal variceal bleeding: a systematic review and network meta-analysis[J]. Hepatology, 2019, 69(4): 1657-1675. DOI: 10.1002/hep.30220.
    [12]
    LO GH, CHEN WC, LIN CK, et al. Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding[J]. Hepatology, 2008, 48(2): 580-587. DOI: 10.1002/hep.22358.
    [13]
    SARIN SK, WADHAWAN M, AGARWAL SR, et al. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding[J]. Am J Gastroenterol, 2005, 100(4): 797-804. DOI: 10.1111/j.1572-0241.2005.40468.x.
    [14]
    REIBERGER T, ULBRICH G, FERLITSCH A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J]. Gut, 2013, 62(11): 1634-1641. DOI: 10.1136/gutjnl-2012-304038.
    [15]
    SHAH HA, AZAM Z, RAUF J, et al. Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial[J]. J Hepatol, 2014, 60(4): 757-764. DOI: 10.1016/j.jhep.2013.11.019.
    [16]
    TRIPATHI D, FERGUSON JW, KOCHAR N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed[J]. Hepatology, 2009, 50(3): 825-833. DOI: 10.1002/hep.23045.
    [17]
    MCDOWELL HR, CHUAH CS, TRIPATHI D, et al. Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study[J]. Aliment Pharmacol Ther, 2021, 53(4): 531-539. DOI: 10.1111/apt.16189.
    [18]
    VILLANUEVA C, ALBILLOS A, GENESCÀ J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial[J]. Lancet, 2019, 393(10181): 1597-1608. DOI: 10.1016/S0140-6736(18)31875-0.
    [19]
    RAFAILIDIS S, DEMERTZIDIS C, BALLAS K, et al. Effect of early propranolol administration on portal hypertensive gastropathy in cirrhotic rats[J]. World J Gastroenterol, 2009, 15(34): 4284-4289. DOI: 10.3748/wjg.15.4284.
    [20]
    GROSZMANN RJ, GARCIA-TSAO G, BOSCH J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis[J]. N Engl J Med, 2005, 353(21): 2254-2261. DOI: 10.1056/NEJMoa044456.
    [21]
    QI XS, BAO YX, BAI M, et al. Nonselective beta-blockers in cirrhotic patients with no or small varices: A meta-analysis[J]. World J Gastroenterol, 2015, 21(10): 3100-3108. DOI: 10.3748/wjg.v21.i10.3100.
    [22]
    MERKEL C, MARIN R, ANGELI P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis[J]. Gastroenterology, 2004, 127(2): 476-484. DOI: 10.1053/j.gastro.2004.05.004.
    [23]
    BHARDWAJ A, KEDARISETTY CK, VASHISHTHA C, et al. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial[J]. Gut, 2017, 66(10): 1838-1843. DOI: 10.1136/gutjnl-2016-311735.
    [24]
    ALBILLOS A, ZAMORA J, MARTÍNEZ J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis[J]. Hepatology, 2017, 66(4): 1219-1231. DOI: 10.1002/hep.29267.
    [25]
    HOLSTER IL, TJWA ET, MOELKER A, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding[J]. Hepatology, 2016, 63(2): 581-589. DOI: 10.1002/hep.28318.
    [26]
    SAUERBRUCH T, MENGEL M, DOLLINGER M, et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy[J]. Gastroenterology, 2015, 149(3): 660-668. DOI: 10.1053/j.gastro.2015.05.011.
    [27]
    LO GH, CHEN WC, WANG HM, et al. Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding[J]. J Gastroenterol Hepatol, 2012, 27(11): 1681-1687. DOI: 10.1111/j.1440-1746.2012.07244.x.
    [28]
    STANLEY AJ, DICKSON S, HAYES PC, et al. Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding[J]. J Hepatol, 2014, 61(5): 1014-1019. DOI: 10.1016/j.jhep.2014.06.015.
    [29]
    YANG J, GE K, CHEN L, et al. The efficacy comparison of carvedilol plus endoscopic variceal ligation and traditional, nonselective β-blockers plus endoscopic variceal ligation in cirrhosis patients for the prevention of variceal rebleeding: a meta-analysis[J]. Eur J Gastroenterol Hepatol, 2019, 31(12): 1518-1526. DOI: 10.1097/MEG.0000000000001442.
    [30]
    JACHS M, HARTL L, SIMBRUNNER B, et al. Carvedilol achieves higher hemodynamic response and lower rebleeding rates than propranolol in secondary prophylaxis[J]. Clin Gastroenterol Hepatol, 2022. DOI: 10.1016/j.cgh.2022.06.007.[Online ahead of print]
    [31]
    SERSTÉ T, MELOT C, FRANCOZ C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites[J]. Hepatology, 2010, 52(3): 1017-1022. DOI: 10.1002/hep.23775.
    [32]
    BANG UC, BENFIELD T, HYLDSTRUP L, et al. Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers[J]. Liver Int, 2016, 36(9): 1304-1312. DOI: 10.1111/liv.13119.
    [33]
    ROBINS A, BOWDEN A, WATSON W, et al. Beta-blockers in cirrhosis patients with refractory ascites[J]. Hepatology, 2014, 59(5): 2054-2055. DOI: 10.1002/hep.26676.
    [34]
    TERGAST TL, KIMMANN M, LASER H, et al. Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis[J]. Aliment Pharmacol Ther, 2019, 50(6): 696-706. DOI: 10.1111/apt.15439.
    [35]
    BOSSEN L, KRAG A, VILSTRUP H, et al. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients[J]. Hepatology, 2016, 63(6): 1968-1976. DOI: 10.1002/hep.28352.
    [36]
    ADAY AW, MAYO MJ, ELLIOTT A, et al. The beneficial effect of beta-blockers in patients with cirrhosis, portal hypertension and ascites[J]. Am J Med Sci, 2016, 351(2): 169-176. DOI: 10.1016/j.amjms.2015.11.018.
    [37]
    WONG RJ, ROBINSON A, GINZBERG D, et al. Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites: A meta-analysis[J]. Liver Int, 2019, 39(6): 1080-1088. DOI: 10.1111/liv.14040.
    [38]
    MANDORFER M, BOTA S, SCHWABL P, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis[J]. Gastroenterology, 2014, 146(7): 1680-1690. DOI: 10.1053/j.gastro.2014.03.005.
    [39]
    TREBICKA J, MACNAUGHTAN J, SCHNABL B, et al. The microbiota in cirrhosis and its role in hepatic decompensation[J]. J Hepatol, 2021, 75(Suppl 1): S67-S81. DOI: 10.1016/j.jhep.2020.11.013.
    [40]
    VILLANUEVA C, ALBILLOS A, GENESCÀ J, et al. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension[J]. Hepatology, 2016, 63(1): 197-206. DOI: 10.1002/hep.28264.
    [41]
    BLASCO-ALGORA S, MASEGOSA-ATAZ J, ALONSO S, et al. Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function[J]. BMJ Open Gastroenterol, 2016, 3(1): e000104. DOI: 10.1136/bmjgast-2016-000104.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (566) PDF downloads(117) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return